Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
March 26, 2024 08:00 ET
|
Opus Genetics
OPGx-LCA5 will advance to the next highest dose in mid-2024 based on positive safety and efficacy data OPGx-LCA5 is well-tolerated and demonstrated clear signs of biological activity RESEARCH...
New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023
November 03, 2023 15:43 ET
|
Opus Genetics
RALEIGH, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced that preliminary data...
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
September 07, 2023 08:02 ET
|
Opus Genetics
OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies ...
Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases
December 28, 2022 08:00 ET
|
Opus Genetics
Opus to advance preclinical development programs for BEST1- and RHO-related retinal diseases Deal expands Opus’ addressable patient population for its novel treatments for rare inherited retinal...
Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
December 01, 2022 08:00 ET
|
Opus Genetics
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in the LCA5 gene, which causes one of the most severe forms of early-onset blinding...
Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases
November 14, 2022 08:00 ET
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the company...
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
September 27, 2022 07:30 ET
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the...
Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
September 12, 2022 08:34 ET
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that Chief...
Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseases
September 01, 2022 08:28 ET
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the release...
Opus Genetics Expands its Leadership Team
July 21, 2022 08:00 ET
|
Opus Genetics
Vikram Arora, Ph.D., DABT, appointed Vice President of Non-Clinical Development Erin O’Neil, M.D., appointed Vice President of Clinical Development Sarah Tuller, J.D., RAC, appointed Vice...